249 related articles for article (PubMed ID: 32601387)
41. Genetic analyses of mosaic neurofibromatosis type 1 with giant café-au-lait macule, plexiform neurofibroma and multiple melanocytic nevi.
Hida T; Idogawa M; Okura M; Sugita S; Sugawara T; Sasaki Y; Tokino T; Yamashita T; Uhara H
J Dermatol; 2020 Jun; 47(6):658-662. PubMed ID: 32246533
[TBL] [Abstract][Full Text] [Related]
42. Cellular Origin, Tumor Progression, and Pathogenic Mechanisms of Cutaneous Neurofibromas Revealed by Mice with
Radomska KJ; Coulpier F; Gresset A; Schmitt A; Debbiche A; Lemoine S; Wolkenstein P; Vallat JM; Charnay P; Topilko P
Cancer Discov; 2019 Jan; 9(1):130-147. PubMed ID: 30348676
[TBL] [Abstract][Full Text] [Related]
43. Culture of cytogenetically abnormal schwann cells from benign and malignant NF1 tumors.
Wallace MR; Rasmussen SA; Lim IT; Gray BA; Zori RT; Muir D
Genes Chromosomes Cancer; 2000 Feb; 27(2):117-23. PubMed ID: 10612798
[TBL] [Abstract][Full Text] [Related]
44. Plexiform neurofibroma: shedding light on the investigational agents in clinical trials.
Acar S; Armstrong AE; Hirbe AC
Expert Opin Investig Drugs; 2022 Jan; 31(1):31-40. PubMed ID: 34932916
[TBL] [Abstract][Full Text] [Related]
45. Role of noncoding RNA ANRIL in genesis of plexiform neurofibromas in neurofibromatosis type 1.
Pasmant E; Sabbagh A; Masliah-Planchon J; Ortonne N; Laurendeau I; Melin L; Ferkal S; Hernandez L; Leroy K; Valeyrie-Allanore L; Parfait B; Vidaud D; Bièche I; Lantieri L; Wolkenstein P; Vidaud M;
J Natl Cancer Inst; 2011 Nov; 103(22):1713-22. PubMed ID: 22034633
[TBL] [Abstract][Full Text] [Related]
46. S100B and neurofibromin immunostaining and X-inactivation patterns of laser-microdissected cells indicate a multicellular origin of some NF1-associated neurofibromas.
Tucker T; Riccardi VM; Brown C; Fee J; Sutcliffe M; Vielkind J; Wechsler J; Wolkenstein P; Friedman JM
J Neurosci Res; 2011 Sep; 89(9):1451-60. PubMed ID: 21674567
[TBL] [Abstract][Full Text] [Related]
47. Plexiform-like neurofibromas develop in the mouse by intraneural xenograft of an NF1 tumor-derived Schwann cell line.
Perrin GQ; Fishbein L; Thomson SA; Thomas SL; Stephens K; Garbern JY; DeVries GH; Yachnis AT; Wallace MR; Muir D
J Neurosci Res; 2007 May; 85(6):1347-57. PubMed ID: 17335073
[TBL] [Abstract][Full Text] [Related]
48. Early administration of imatinib mesylate reduces plexiform neurofibroma tumor burden with durable results after drug discontinuation in a mouse model of neurofibromatosis type 1.
Armstrong AE; Rhodes SD; Smith A; Chen S; Bessler W; Ferguson MJ; Jiang L; Li X; Yuan J; Yang X; Yang FC; Robertson KA; Ingram DA; Blakeley JO; Clapp DW
Pediatr Blood Cancer; 2020 Aug; 67(8):e28372. PubMed ID: 32459399
[TBL] [Abstract][Full Text] [Related]
49. P2RY14 cAMP signaling regulates Schwann cell precursor self-renewal, proliferation, and nerve tumor initiation in a mouse model of neurofibromatosis.
Patritti Cram J; Wu J; Coover RA; Rizvi TA; Chaney KE; Ravindran R; Cancelas JA; Spinner RJ; Ratner N
Elife; 2022 Mar; 11():. PubMed ID: 35311647
[TBL] [Abstract][Full Text] [Related]
50. Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow.
Yang FC; Ingram DA; Chen S; Zhu Y; Yuan J; Li X; Yang X; Knowles S; Horn W; Li Y; Zhang S; Yang Y; Vakili ST; Yu M; Burns D; Robertson K; Hutchins G; Parada LF; Clapp DW
Cell; 2008 Oct; 135(3):437-48. PubMed ID: 18984156
[TBL] [Abstract][Full Text] [Related]
51. Analysis of somatic NF1 promoter methylation in plexiform neurofibromas and Schwann cells.
Fishbein L; Eady B; Sanek N; Muir D; Wallace MR
Cancer Genet Cytogenet; 2005 Mar; 157(2):181-6. PubMed ID: 15721644
[TBL] [Abstract][Full Text] [Related]
52. A chance to cut is a chance to cure: complete resection of an atypical neurofibroma prevents further progression to malignancy.
Vaassen P; Feldkamp A; Scholz M; Blau T; Dürr NR; Rosenbaum T
Childs Nerv Syst; 2023 Nov; 39(11):3301-3304. PubMed ID: 37344677
[TBL] [Abstract][Full Text] [Related]
53. Clinic-based study of plexiform neurofibromas in neurofibromatosis 1.
Waggoner DJ; Towbin J; Gottesman G; Gutmann DH
Am J Med Genet; 2000 May; 92(2):132-5. PubMed ID: 10797438
[TBL] [Abstract][Full Text] [Related]
54. MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.
de Blank PMK; Gross AM; Akshintala S; Blakeley JO; Bollag G; Cannon A; Dombi E; Fangusaro J; Gelb BD; Hargrave D; Kim A; Klesse LJ; Loh M; Martin S; Moertel C; Packer R; Payne JM; Rauen KA; Rios JJ; Robison N; Schorry EK; Shannon K; Stevenson DA; Stieglitz E; Ullrich NJ; Walsh KS; Weiss BD; Wolters PL; Yohay K; Yohe ME; Widemann BC; Fisher MJ
Neuro Oncol; 2022 Nov; 24(11):1845-1856. PubMed ID: 35788692
[TBL] [Abstract][Full Text] [Related]
55. Allelic loss of the NF1 gene in NF1-associated plexiform neurofibromas.
Kluwe L; Friedrich RE; Mautner VF
Cancer Genet Cytogenet; 1999 Aug; 113(1):65-9. PubMed ID: 10459349
[TBL] [Abstract][Full Text] [Related]
56. Mosaic Neurofibromatosis Type 1 With Multiple Cutaneous Diffuse and Plexiform Neurofibromas of the Lower Leg.
Friedrich RE; Hagel C; Kohlrusch FK; Schanze I; Wieland I; Zenker M
Anticancer Res; 2020 Jun; 40(6):3423-3427. PubMed ID: 32487640
[TBL] [Abstract][Full Text] [Related]
57. Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review.
Solares I; Viñal D; Morales-Conejo M; Rodriguez-Salas N; Feliu J
ESMO Open; 2021 Aug; 6(4):100223. PubMed ID: 34388689
[TBL] [Abstract][Full Text] [Related]
58. Identification of potential common genetic modifiers of neurofibromas: a genome-wide association study in 1333 patients with neurofibromatosis type 1.
Pacot L; Sabbagh A; Sohier P; Hadjadj D; Ye M; Boland-Auge A; Bacq-Daian D; Laurendeau I; Briand-Suleau A; Deleuze JF; Margueron R; Vidaud M; Ferkal S; Parfait B; Vidaud D; ; Pasmant E; Wolkenstein P
Br J Dermatol; 2024 Jan; 190(2):226-243. PubMed ID: 37831592
[TBL] [Abstract][Full Text] [Related]
59. Modeling iPSC-derived human neurofibroma-like tumors in mice uncovers the heterogeneity of Schwann cells within plexiform neurofibromas.
Mazuelas H; Magallón-Lorenz M; Fernández-Rodríguez J; Uriarte-Arrazola I; Richaud-Patin Y; Terribas E; Villanueva A; Castellanos E; Blanco I; Raya Á; Chojnacki J; Heyn H; Romagosa C; Lázaro C; Gel B; Carrió M; Serra E
Cell Rep; 2022 Feb; 38(7):110385. PubMed ID: 35172160
[TBL] [Abstract][Full Text] [Related]
60. Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINT.
Gross AM; Achée C; Hart SE; Brewer L; Baldwin A; Wolters PL; Widemann BC;
Future Oncol; 2024 May; 20(14):877-890. PubMed ID: 38869947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
